Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies

Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies

Abstract Background Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies. Methods Clinical routine data of highly resistant migraine patients were analyzed before treatment with CGRP m...

Full description

Bibliographic Details
Main Authors: Michael Nsaka, Armin Scheffler, Sebastian Wurthmann, Hannah Schenk, Christoph Kleinschnitz, Martin Glas, Dagny Holle
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Brain and Behavior
Subjects:
CGRP (pathway) antibodies
disease modification
guidelines
migraine
one‐year prophylactic treatment
treatment break
Online Access:https://doi.org/10.1002/brb3.2662

Internet

https://doi.org/10.1002/brb3.2662

Similar Items